NCT06685185View on ClinicalTrials.gov

A Research Study of a New Medicine NNC0363-1063 in Healthy Participants and Participants With Type 1 Diabetes

PHASE1RecruitingINTERVENTIONAL
Enrollment

154

Participants

Timeline

Start Date

November 12, 2024

Primary Completion Date

May 15, 2026

Study Completion Date

May 15, 2026

Conditions
Diabetes Mellitus, Type 1
Interventions
DRUG

NNC0363-1063

NNC0363-1063 will be administered subcutaneously.

DRUG

Placebo

Placebo will be administered subcutaneously.

DRUG

Insulin degludec

Insulin degludec will be administered subcutaneously.

DRUG

Insulin detemir

Insulin detemir will be administered subcutaneously.

Trial Locations (1)

41460

RECRUITING

Profil Institut für Stoffwechselforschung GmbH, Neuss

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY